Controlling Ice Nucleation During the Freezing Step of Lyophilization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Controlling Ice Nucleation During the Freezing Step of Lyophilization
Lyophilization technologies for controlled nucleation.


Pharmaceutical Technology
Volume 37, Issue 5, pp. 36-40


PHOTO 24/MARIA TOUTOUDAKI/GETTY IMAGES; DAN WARD
Lyophilization, or freeze drying, is an important manufacturing step widely used to increase the stability of pharmaceutical and biological products. Developed during the 1940s, lyophilization produces a dry product that can be readily reconstituted to its original form by adding water when required (1). It prolongs product shelf life by inhibiting chemical, microbiological, and physical degradation pathways that occur in the presence of moisture, particularly where long periods of storage and transit prior to use are involved (1, 2).

The lyophilization process consists of three main stages—freezing (solidification), primary drying (ice sublimation), and secondary drying (moisture desorption)—and usually takes several days to complete. Multiple vials containing a liquid drug formulation are loaded on temperature-controlled shelves within a sterile chamber and cooled to low temperatures until completely solidified (2). After that, chamber pressure is reduced and shelf temperature is raised to remove the frozen solvent through sublimation. The remaining unfrozen solvent that is chemically bound to the solid product is removed by a desorption process (3). The drying process is concluded by stoppering the vials in the chamber, generally under a subambient pressure of inert gas. The final dry product, called a cake, usually occupies approx-imately the same volume as the initial liquid fill because of its high porosity (2). "To ensure that high quality products are consistently produced, it is crucial to be able to control and provide repeatability of the lyophilization cycles," says Joseph Brower, technology manager at IMA Life North America.

The freezing step

The freezing step is one of the most important steps in lyophilization because it determines the texture of the frozen material and consequently, the final morphological characteristics of the freeze-dried material and its biological activity stability (4). "Proper freezing creates the foundation for efficient and consistent freeze-drying cycles," says T.N. Thompson, president of Millrock Technology, a company that develops freeze drying/lyophilization systems for laboratory applications and cGMP production.

The three steps in the freezing process are nucleation, crystallization of the freeze concentrate, and for the maximal freeze concentrate, either freeze separation in eutectic products or concentration in amorphous products. The parameters of the freezing protocol directly affect pore size distribution and pore connectivity of the porous network of the freeze-dried matrix. The ice-crystal morphology determines both mass and heat transfer rates through the dry layer and as a result, freezing parameters have a strong influence on the total duration of the primary and secondary drying steps (4).

The nucleation process

During the freezing phase of a typical freeze-drying cycle, the nucleation process of which the first solid domains are formed occurs randomly in the vials. "In an uncontrolled environment, due to the lack of nucleation sites in pure systems, the formulation solution must be cooled down to temperatures that are significantly lower than the equilibrium freezing point (i.e., supercooled) to initialize formation of ice crystals," Brower explains.

The contents of individual vials often nucleate or begin freezing over a broad range of temperatures, "usually spanning 10–15 C below the formulation's thermo-dynamic freezing point in a laboratory freeze dryer and 20 C or greater in a cGMP Class 100 production dryer," says Mark Shon, vice-president of sales and marketing at SP Scientific. This supercooling phenomenon creates significant vial-to-vial heterogeneity in the solid microstructure, which significantly affects the subsequent drying processes. "To accommodate this heterogeneity, today's best practice is to design lyophilization processes for the worst-case scenarios; however, this strategy can result in excessively long drying cycles, broad product specifications, longer process development times, and nonoptimal product preservation," comments Cheryl Thierfelder, Praxair's business development manager.

It has long been recognized that one of the most important goals during the freezing step of lyophilization is to produce a uniform batch, which is a challenge due to the stochastic nature of nucleation. The random nature of nucleation, however, makes it difficult to control the nucleation temperature and maintain it within the desirable supercooling range.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here